Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib for Anti-PD1 Induced Lichenoid Skin Toxicities
NCT06399029Phase 2Active, not recruiting
- Sponsor
- University of Zurich
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in lichenoid dermatitis, sponsored by University of Zurich. Primary endpoint: Proportion of patients achieving at least 90% improvement of rash at 12 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
lichenoid dermatitis
Beyond the preview
Go deeper on NCT06399029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399029.